An update on the biologics for the treatment of antiphospholipid syndrome

Abstract

Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by thrombosis and pregnancy morbidity with the persistent presence of antiphospholipid antibodies (aPLs). Although anticoagulation is the primary treatment for APS, it fails in approximately 20-30% of obstetric APS cases and more than 30% of thrombotic APS cases. Therefore, there is a need for new, targeted treatments beyond anticoagulants. Biologics, such as rituximab and eculizumab, have been recommended for refractory catastrophic APS. This review focuses on the recent advancements in the pathogenesis of APS and explores the potential of targeted treatments, including eculizumab, rituximab, belimumab, daratumumab, obinutuzumab, and anti-TNF-α antibodies, for APS management.

Antiphospholipid syndrome in cardiovascular disease and cancer

“…The use of direct oral anticoagulants is still under investigation, as well as new biologic target treatments such as Eculizumab, Belimumab, and Obinutuzumab. 59,60 The available therapies for APS are considered limited compared to other pathologies. Anticoagulation treatment, with administration of warfarin, various vitamin K antagonists, is the only treatment used to reduce the overall risk of recurrent thrombosis.…”